Prof. Dr. Mahmut Emre Yıldırım
Is this your profile? Claim it and verify your details.
Claim profilePerson ↔ Disease
Which diseases does this doctor work on?
-
Breast Neoplasms 8 publicationsSource: OpenAlex / PubMed MeSHView publications
- Colorectal Neoplasms 4 publications
- Colonic Neoplasms 3 publications
- Lung Neoplasms 3 publications
- Neoplasms 3 publications
- Liver Neoplasms 2 publications
- Adenocarcinoma 2 publications
Person ↔ Disease
Which topics does this doctor work on?
Medical areas of interest stated by the doctor on the institution profile. Source: medicalpark.com.tr.
- Hedefe yönelik tedaviler
- İmmunoterapi
- Jinekolojik tümörler
- Akciğer kanseri
- Meme kanseri
- Gastrointestinal kanserler
- Ürolojik tümörler
- Nadir tümörler
CV
Education and experience
Education
- 19952002 İstanbul Üniversitesi Cerrahpaşa Tıp Fakültesimedicalpark.com.tr
- 20022008 İstanbul Üniversitesi Cerrahpaşa Tıp Fakültesi İç Hastalıkları İhtisasımedicalpark.com.tr
- 20082009 Fatih Sultan Mehmet Eğitim ve Araştırma Hastanesi İç Hastalıklarımedicalpark.com.tr
- 20092012 Kartal Dr. Lütfi Kırdar Eğitim ve Araştırma Hastanesi Tıbbi Onkoloji İhtisasımedicalpark.com.tr
- 20132015 Ankara Dr. Zekai Tahir Burak Kadın Sağlığı Eğitim ve Araştırma Hastanesi Tıbbi Onkolojimedicalpark.com.tr
- Education2015 Kartal Dr. Lütfi Kırdar Eğitim ve Araştırma Hastanesi Tıbbi Onkoloji Başasistanmedicalpark.com.tr
- 2017Tıbbi Onkoloji Doçentimedicalpark.com.tr
- 20172023 Kartal Dr. Lütfi Kırdar Şehir Hastanesi Tıbbi Onkoloji Kliniği Eğitim ve İdari Sorumlusu Sağlık Bilimleri Üniversitesi Öğretim Üyesimedicalpark.com.tr
Trust
Where does this information come from?
The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.
- SpecialtyMedical Oncologymedicalpark.com.trFrom source
- Department name at the sourceMedikal Onkoloji (Tıbbi Onkoloji)medicalpark.com.trFrom source
- InstitutionMedical Park Pendikmedicalpark.com.trFrom source
- Area of workBreast NeoplasmsExtracted from 8 publications · Model version —From source
- Publications52 publicationsOpenAlex, ORCIDFrom source
- ORCID0000-0002-5360-5949ORCIDFrom source
- Last synchronised4 November 2026 20:28https://www.medicalpark.com.tr/hekimler/mahmut-emre-yildirimmedicalpark.com.tr
Scientific work
Publications on Breast Neoplasms
-
Real-world practices in RAS wild-type metastatic colorectal cancer patients treated with targeted agents in the first-line a nationwide onco-colon Turkey registry
Anadolu Kliniği Tıp Bilimleri Dergisi, 2026
DOI 10.21673/anadoluklin.1675424 Open-access full textSource: OpenAlex
-
Clinical Characteristics, Treatment Patterns, and Survival Outcomes of Right-Sided RAS/RAF Wild-Type Metastatic Colorectal Cancer: A Real-World Multicenter Cohort Study
Clinics and Practice, 2026
DOI 10.3390/clinpract16090158 PMID 42783081 Open-access full textSource: OpenAlex
-
Real-World Survival Outcomes Following Metastasectomy in RAS Wild-Type mCRC: Insights from a Multicentre National Cohort Study
Journal of Clinical Medicine, 2026
DOI 10.3390/jcm15020467 PMID 41598406 Open-access full textSource: ORCID
-
Expression and prognostic importance of lymphocyte activation gene 3 and CD73 in advanced or metastatic hepatocellular carcinoma
Journal of International Medical Research, 2026
DOI 10.1177/03000605251386599 PMID 41521150 Open-access full textSource: OpenAlex
-
Prognostic Value of the Cancer Inflammation Prognostic Index (CIPI) in De Novo Metastatic Colon Cancer: A Multicenter Retrospective Cohort Study
Cancer Control, 2026
DOI 10.1177/10732748261432273 PMID 41779425 Open-access full textSource: ORCID
-
Prognostic Factors in Advanced Bladder Cancer: A Real-World Retrospective Analysis
Haydarpaşa Numune medical journal (Online), 2026
DOI 10.14744/hnhj.2026.82997 Open-access full textSource: OpenAlex
-
KRAS Mutasyonu Saptanmayan Metastatik Kolorektal Kanserli Hastalarda Anti-EGFR Kullanımı-Ulusal Onco-Colon Çalışması Gerçek Yaşam Verleri
DergiPark (Istanbul University), 2025
Source: OpenAlex
-
The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysis
BMC Cancer, 2025
DOI 10.1186/s12885-025-14252-3 PMID 40329228 3 citations (Europe PMC) Open-access full textSource: OpenAlex
-
Evaluating the Effectiveness of Cyclin-Dependent Kinase 4/6 Inhibitors in Early- and Very Early-Onset Metastatic Breast Cancer: A Multicenter Study
Medicina, 2025
DOI 10.3390/medicina61010154 PMID 39859134 2 citations (Europe PMC) Open-access full textSource: ORCID
-
Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC
Journal of Oncology Pharmacy Practice, 2024
DOI 10.1177/10781552241241004 PMID 38613329 Open-access full textSource: OpenAlex